SCHEMBL4985533

SCHEMBL4985533

CCN1CCN(c2ccc(C(N)=O)c(C3=CCCCC3)c2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.43
KIT P10721 1/20 0.43
GAA P10253 2/20 0.41
RAD52 P43351 2/20 0.41
PSMB5 P28074 2/20 0.41
PSMB1 P20618 1/20 0.41
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GFER P55789 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TMEM97 Q5BJF2 2/20 0.37
SIGMAR1 Q99720 2/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
POLB P06746 1/20 0.36
ADRB2 P07550 2/20 0.36
ADRB1 P08588 2/20 0.36
ADRB3 P13945 2/20 0.36
ADRA1D P25100 2/20 0.36
ADRA1A P35348 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2912399 0.87 CSF1R (0.54) CSF1RKITGAAPSMB5PSMB1
SCHEMBL4985541 0.82 GAA (0.56) CSF1RKITGAARAD52PSMB5
SCHEMBL15418560 0.76 CHEK1 (0.45) CSF1RKITGRM2LMNA
SCHEMBL3226851 0.76 GAA (0.62) GAARAD52MAPTKDM4EGFER
SCHEMBL24663011 0.73 GAA (0.62) GAARAD52MAPTKDM4EGFER
SCHEMBL3216850 0.73 GAA (0.58) GAARAD52MAPTKDM4EGFER
SCHEMBL3076858 0.73 CSF1R (0.48) CSF1RGAAGRM2
SCHEMBL3092798 0.72 CSF1R (0.41) CSF1RPSMB5MAPTSMN1; SMN2GRM2
Hydrochloric Acid SCHEMBL4179578 0.72 CSF1R (0.52) CSF1RKITSMN1; SMN2GRM2ALDH1A1
SCHEMBL3076846 0.72 PSMB5 (0.46) CSF1RGAAPSMB5MAPTGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8697716-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2014-04-15 US disclosed
US-20080051402-A1 METHOD OF INHIBITING C-KIT KINASE JANSSEN PHARMACEUTICA NV (BE) 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051402-A1 METHOD OF INHIBITING C-KIT KINASE KIT, CHUK, MAP3K13 CSF1R 2973/4885KIT 1/4885GAA 969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.